Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01103414 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

A Phase 2 study of Type 2 Diabetes, sponsored by Metabolic Solutions Development Company.

Completed
Registry status
Phase 2
Development phase
356
Enrollment target
20
Study locations

NCT01103414 is a Phase 2 study of Type 2 Diabetes that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 356 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01103414, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Metabolic Solutions Development Company.

COMPLETED
Registry status
Phase 2
Development phase
356 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone
  • DRUG Mitoglitazone

Study Locations (20)

California

  • - Chino
  • - Los Angeles
  • - Spring Valley
  • - Walnut Creek

Florida

  • - Miami
  • - New Port Richley
  • - Palm Harbor
  • - Pembroke Pines

Ohio

  • - Cincinnati
  • - Kettering
  • - Tiffin

Alabama

  • - Huntsville
  • - Muscle Shoals

Oregon

  • - Eugene
  • - Portland

Georgia

  • - Marietta

Illinois

  • - Chicago

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 356 participants
Start Date 2010-09
Est. Completion 2011-12
Phase Phase 2

Sponsor

Metabolic Solutions Development Company

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01103414

The ClinicalTrials.gov registry entry for NCT01103414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (68% lower). The listed sponsor is Metabolic Solutions Development Company, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01103414 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT01103414 about?

NCT01103414 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients". The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.

What is the current status of trial NCT01103414?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2010-09. Estimated completion is 2011-12.

What conditions does trial NCT01103414 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT01103414?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Mitoglitazone (DRUG).

Who is sponsoring clinical trial NCT01103414?

This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01103414 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.